Revenue FY2025
—
Net Income
$(125.0M)
EPS (Basic)
$-0.44
Net Margin
—
ROE
-38.3%
Total Equity
$325.0M
Shares Out
350M
Erasca, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 5 funds in our universe
Insider Transactions
Reading stored insider transactions…